HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease.

Abstract

Iron metabolism has been implicated in carcinogenesis and several studies assessed the potential role of genetic variants of proteins involved in iron metabolism (HFE C282Y, TFR S142G) in different malignancies. Few reports addressed this issue with relation to chronic myeloproliferative disorders (CMPD). The aims of our study were (a) to examine the potential associations of CMPD development with genetic modifiers of iron metabolism in a large cohort of CMPD patients; (b) to examine associations of genetic variants of proteins involved in iron metabolism; and acquired JAK2 V617F mutation with clinical characteristics of CMPD. HFE C282Y was genotyped in 328 CMPD patients and 996 blood donors as controls, HFE H63D, and TFR S142G were tested in CMPD patients and 171 first time blood donors. JAK2 V617F mutation was tested in CMPD patients and in 122 repeated blood donors. Decreased C282Y allele frequency (allele frequency+/-95% confidence interval) was found in the CMPD group (1.8%+/-1.0%) compared with controls (3.4%+/-0.8%; P=0.048). TFR S142G allele frequency was reduced among V617F-negative CMPD patients (34.8%+/-7.6%) compared with controls (47.8%+/-5.4%; P=0.02). The frequency of JAK2 V617F was 75.9% (249 of 328) in the CMPD group. At presentation, elevated hemoglobin levels were found in V617F-positive patients compared with V617F-negative counterparts (P<0.000). Vascular complications (26.6% versus 15.2%; P=0.039) as well as female gender (57.4% versus 41.8%; P=0.019) were more common in V617F-positive patients. We found that HFE C282Y might be associated with a protective role against CMPD. Because chronic iron deficiency or latent anemia may trigger disease susceptibility for CMPD, HFE C282Y positivity may be a genetic factor influencing this effect.

DOI: 10.1158/1055-9965.EPI-08-0359

2 Figures and Tables

Cite this paper

@article{Andrikovics2009HFECM, title={HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease.}, author={Hajnalka Andrikovics and N{\'o}ra Meggyesi and Anik{\'o} Szilv{\'a}si and J{\'u}lia Tam{\'a}ska and Gabriella Halm and S{\'a}ndor Lueff and Sarolta Nahajevszky and Mikl{\'o}s Egyed and Judit V{\'a}rkonyi and Gabor Mikala and Andrea Sipos and Laszlo Kalasz and Tamas Masszi and Attila Tordai}, journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}, year={2009}, volume={18 3}, pages={929-34} }